We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+39.82%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11.4B
AUM Growth
+$3.47B
Cap. Flow
+$1.27B
Cap. Flow %
11.12%
Top 10 Hldgs %
37.58%
Holding
169
New
25
Increased
27
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$384M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$292M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$154M
4
PFE icon
Pfizer
PFE
+$133M
5
UNH icon
UnitedHealth
UNH
+$131M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$259M
2
XLRN
Acceleron Pharma
XLRN
+$67.6M
3
ASND icon
Ascendis Pharma A/S
ASND
+$65.8M
4
EXEL icon
Exelixis
EXEL
+$58.8M
5
BIIB icon
Biogen
BIIB
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.2%
2 Financials 0.52%
3 Technology 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APTO
76
DELISTED
Aptose Biosciences, Inc.
APTO
$35.2M 0.31%
17,844
+15,849
+794% +$37.2M
QURE icon
77
uniQure
QURE
$2.72B
$35M 0.31%
969,079
– –
MOH icon
78
Molina Healthcare
MOH
$10.5B
$34.5M 0.3%
+162,400
New +$33.5M
ALEC icon
79
Alector
ALEC
$169M
$33.6M 0.29%
2,225,313
-500,000
-18% -$6.21M
SYRE icon
80
Spyre Therapeutics
SYRE
$8.31B
$31.6M 0.28%
160,621
– –
OLMA icon
81
Olema Pharmaceuticals
OLMA
$983M
$31.3M 0.27%
+650,992
New +$30.5M
CTIC
82
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$30.7M 0.27%
9,520,600
– –
HARP
83
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$30.5M 0.27%
183,570
– –
NXTC icon
84
NextCure
NXTC
$21.9M
$29.6M 0.26%
225,918
– –
NBP
85
NovaBridge Biosciences American Depositary Shares
NBP
$191M
$28.6M 0.25%
606,070
– –
OSH
86
DELISTED
Oak Street Health, Inc.
OSH
$27.4M 0.24%
448,100
+113,700
+34% +$5.97M
FLXN
87
DELISTED
Flexion Therapeutics, Inc.
FLXN
$26.6M 0.23%
2,308,083
+624,083
+37% +$7.25M
ALXN
88
DELISTED
Alexion Pharmaceuticals
ALXN
$26.4M 0.23%
169,000
-2,015,500
-92% -$259M
SNDX icon
89
Syndax Pharmaceuticals
SNDX
$1.67B
$26M 0.23%
1,170,900
+76,800
+7% +$1.59M
SCPH
90
DELISTED
scPharmaceuticals
SCPH
$25.4M 0.22%
4,797,148
– –
HRTX icon
91
Heron Therapeutics
HRTX
$92.3M
$25.2M 0.22%
1,191,846
– –
CRVS icon
92
Corvus Pharmaceuticals
CRVS
$1.1B
$24.1M 0.21%
6,767,584
– –
SRRA
93
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$23.7M 0.21%
1,477,320
– –
ALC icon
94
Alcon
ALC
$34.1B
$23.4M 0.2%
351,380
– –
LAB icon
95
Standard BioTools
LAB
$326M
$23.4M 0.2%
3,892,346
+338,643
+10% +$2.22M
NMTR
96
DELISTED
9 Meters Biopharma
NMTR
$22.1M 0.19%
1,285,838
– –
PAND
97
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$22M 0.19%
1,480,940
– –
PRTA icon
98
Prothena Corp
PRTA
$442M
$21.6M 0.19%
1,797,458
-1,747,017
-49% -$20.7M
AMGN icon
99
Amgen
AMGN
$211B
$21M 0.18%
91,500
– –
OTIC
100
DELISTED
Otonomy, Inc.
OTIC
$21M 0.18%
3,250,000
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2020 Portfolio in Review

As of Q4 2020, OrbiMed held 169 positions worth $11.4B, up 44% from $7.96B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $1.27B of net new capital in Q4 2020, opening 25 new positions and adding to 27 existing holdings. Its largest new stake was AbCellera Biologics: 8,400,768 shares worth $338M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $259M trimmed.

  • OrbiMed's largest Q4 2020 buy was AbCellera Biologics: 8,400,768 shares worth $338M.
  • OrbiMed added most to Xtant Medical Holdings in Q4 2020, an estimated $81.8M increase.
  • OrbiMed's biggest Q4 2020 reduction was Alexion Pharmaceuticals, cutting an estimated $259M.
  • OrbiMed fully exited Acceleron Pharma in Q4 2020, selling an estimated $67.6M.
  • OrbiMed's ten largest holdings make up 38% of its $11.4B portfolio in Q4 2020.
  • OrbiMed opened 25 new positions and closed 20 in Q4 2020.
  • OrbiMed's portfolio value rose 44% quarter-over-quarter to $11.4B.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.